Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)

BACKGROUND: Few prospective studies have compared the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors. We aimed to clarify the efficacy of dapagliflozin versus sitagliptin for modulating cardiometabolic risk factors including...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cardiovasc Diabetol
Huvudupphovsmän: Fuchigami, Ayako, Shigiyama, Fumika, Kitazawa, Toru, Okada, Yosuke, Ichijo, Takamasa, Higa, Mariko, Hiyoshi, Toru, Inoue, Ikuo, Iso, Kaoru, Yoshii, Hidenori, Hirose, Takahisa, Kumashiro, Naoki
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2020
Ämnen:
Original Investigation
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6945792/
https://ncbi.nlm.nih.gov/pubmed/31910850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-019-0977-z
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk